N/A N=37 Biobehavioral Pathways Underlying Alcohol Use and Health
Alcohol Use Disorder · Liver Diseases
Primary: Percentage of Screen Eligible Who Enroll — 28; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Acute Alcohol Response In Bipolar Disorder: a fMRI Study
Bipolar Disorder · Alcohol Drinking · Alcohol Use Disorder
Primary: Level of Intoxication (Subjective Response) on Each Condition Day After Drinking Relative to How They Felt When Arriving to the Lab on That Respective Day )Prior to…
N/A N=185 Pioglitazone for the Treatment of Alcohol Use Disorder
Alcohol Use Disorder
Primary: Heavy Drinking Days Per Week Change — -1.76; -2.3 Mean heavy drinking days per week
Phase 2 N=12 Modafinil for the Treatment of Alcohol Use Disorders
Alcohol Use Disorder
Primary: Time to Relapse — 16; 43 days
Phase 2 N=48 Semaglutide for Alcohol Use Disorder
Alcohol Use Disorder · Cigarette Smoking
Primary: Change in Alcohol Consumed — -32.72; -6.95 grams
N/A N=134 Records for Alcohol Care Enhancement
Alcohol Use Disorder (AUD)
Primary: Percent of New Alcohol Use Disorder (AUD) Diagnosis Episodes That Meet Criteria for AUD Treatment Engagement Among Patients With a New AUD Diagnosis Who Are Empaneled to…
N/A N=2 Deep Brain Stimulation for Alcohol Use Disorder
Alcohol Use Disorder
Primary: Number of Serious Adverse Events (Safety and Tolerability) — 1; 1 Adverse Events
Phase 2 N=4 Open Label Pilot Study of Perampanel for the Treatment of Alcohol Use Disorder
Alcohol Disorders
Primary: Percent Abstinent Days — 3.13; 100 Percentage of days
Phase 2 N=27 Collaborative Care for Alcohol Use Disorders in the Patient-centered Medical Home
Alcohol-Related Disorders · Alcohol Drinking · Alcoholism
Primary: Weekly Change in Drinking — -11.4; -22.2; -39.6; -29.3 score on a scale
N/A N=3 Pilot Human Laboratory Study of Alcohol Approach Bias Modification (AABM) for Alcohol Use Disorder (AUD)
Alcohol Use Disorder
Primary: Recruitment Feasibility — 3 Participants
Phase 3 N=75 Aripiprazole for Bipolar Disorder and Alcohol Use Disorder
Bipolar Disorder · Alcoholism · Alcohol Abuse
Primary: Timeline Follow Back (TLFB) — -0.82; -0.71 drinks per drinking day
Phase 3 N=40 Glutamatergic Modulation of Disordered Alcohol Use
Alcohol Dependence
Primary: Percentage of Participants Demonstrating Alcohol Abstinence in the Control (Midazolam) Group Versus the Active (Ketamine) Group — 68.6; 98.6 percentage of participants
Phase 2 N=18 Pregabalin as Treatment for Alcohol Use Disorder
Alcohol Use Disorder
Primary: Maximum Dose of Pregabalin: — 571.4 milligrams
Phase 1 N=91 The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders
Alcohol Use Disorder
Primary: Percent Drinking Days — 38.5; 46.6; 53 percentage of drinking days — p=0.009
N/A N=75 Clinical Intervention in Alcohol Use Disorder
Alcohol Use Disorder · Eligible to go Into the MRI Scanner · Short-term Abstinence From Alcohol Use (2 Week Abstinent)
Primary: Intervention Effects on Brain Functional Connectivity — 0.05; 0.19 percentage of Blood Oxygenation Level De
Phase 2 N=27 Effects of Cannabidiol in Alcohol Use Disorder
Alcohol Use Disorder
Primary: Trough CBD Plasma Levels — 0; 0.7 CBD (ng/mL)
Phase 2 N=60 Human Laboratory Study of ASP8062 for Alcohol Use Disorder
Alcohol Use Disorder · Alcohol Drinking · Alcohol Use Disorder (AUD)
Primary: Alcohol Craving — 6.44; 6.26 score on a scale — p=0.784
Phase 2 N=13 An Open-Label, Single Dose Study in Patients With Alcohol Use Disorder
Alcohol Use Disorder
Primary: Percentage of Participants With Treatment Emergent Adverse Events — 11 Participants
Phase 2 N=100 Intranasal Oxytocin for the Treatment of Alcohol Use Disorder
Alcohol Use Disorder · Alcohol Misuse
Primary: Weekly Percentage of Heavy Drinking Days — 51.5; 52.9 percentage of days per week
N/A N=285,304 Sustaining Patient-centered Alcohol-related Care
Alcohol, Drinking · Alcohol Use Disorder
Primary: Brief Alcohol Counseling Rate — 57; 11 participants per 10,000 with visits — p=<.001
Phase 4 N=96 Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders
Alcohol Use Disorder · Bipolar Disorder · Schizoaffective Disorder Bipolar Type
Primary: Baseline-to-Exit Change in Drinks Per Drinking Day (TLFB) — -1.98; -2.82; -1.22 Standard Drinks per Drinking Day
Phase 2 N=50 Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo
Alcohol Use Disorder
Primary: Craving to Drink — 31.1; 33.2 score on a scale — p=.065
Phase 2 N=102 Ibudilast for the Treatment of Alcohol Use Disorder
Alcohol Use Disorder
Primary: Percent Heavy Drinking Days — 67.4777; 65.65447; 53.88376; 42.96028 percent of heavy drinking days
Phase 2 N=21 Manipulating Ghrelin Signaling Via GOAT Inhibition in Alcohol Use Disorder
Alcohol Use Disorder
Primary: Number of Participants With Adverse Events (AEs) — 18; 15 Participants
N/A N=48 Alcohol Use and Chronic Pain Among Primary Care Patients
Alcohol Drinking · Chronic Pain
Primary: Alcohol Time Line Followback (30)- Heavy Drinking Episode Days in the Past 30 Days — 7.9; 4.3 heavy drinking days
N/A N=558 Mobile Health for Alcohol Use Disorders in Clinical Practice
Alcohol Drinking · Telemedicine
Primary: Percentage of Heavy Drinking Days, PHDD — 24.4; 21.4; 21.3 percentage of heavy drinking days — p=0.688
N/A N=120 Coping Skills for Alcohol Use
Alcohol Drinking · Coping Skills
Primary: Alcohol Use-Peak Drinks — 4.71; 4.79 number of drinks — p=>.05
Phase 4 N=41 Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder
Alcohol Dependence · Anxiety Disorder
Primary: Treatment Adherence — 15 Participants
Phase 2 N=11 Development of Ivermectin for Alcohol Use Disorders
Alcohol Use Disorder
Primary: Heart Rate — 64.57; 68.36; 66.82; 62.82 BPM — p=0.0563
Phase 2 N=103 Mifepristone Treatment of Alcohol Use Disorder
Alcohol Dependence · Alcohol Use Disorders · Alcohol Abuse
Primary: Drinking Quantity Per Day — 1.25; 1.38; 1.10 Standard drinks per day — p=0.51